Related Experiment Video
Updated: Dec 31, 2025

Mass Cytometry Analysis of Systemic and Local Immune Responses in Hepatocellular Carcinoma
Published on: April 25, 2025
Mass cytometry defines distinct immune profile in germinal center B-cell lymphomas
Mikael Roussel1,2, Faustine Lhomme3, Caroline E Roe4,5
1Laboratoire Hématologie, CHU Pontchaillou, Centre Hospitalier Universitaire de Rennes, Pôle Biologie, 2 rue Henri Le Guilloux, 35033, Rennes, France. mikael.roussel@chu-rennes.fr.
Insights
Tumor-associated macrophages (TAMs) in lymphoma exhibit distinct phenotypes, differing from normal macrophages. These abnormal TAMs correlate with T-cell states, suggesting new therapeutic targets in cancer immunotherapy.
Area of Science:
- Immunology
- Oncology
- Cell Biology
Background:
- Tumor-associated macrophages (TAMs) and T-cell subsets play roles in lymphoma pathogenesis.
- Macrophages contribute to tumor immune evasion via checkpoint ligands and suppressive cytokines.
- Macrophage polarization states in lymphoma are less understood than T-cell subsets.
Purpose of the Study:
- To investigate and characterize macrophage polarization states within B-cell lymphoma tumor microenvironments.
- To identify distinct intra-tumor macrophage subsets and their association with lymphoma types.
- To explore the relationship between macrophage and T-cell phenotypes in lymphoma.
Main Methods:
- Application of a mass cytometry panel for myeloid-derived suppressor cells and macrophage states.
- High-dimensional single-cell analysis using dimensionality reduction and clustering.
- Characterization of B-lymphoma tumors and non-malignant human tissue.
Main Results:
- Identification of phenotypically distinct intra-tumor macrophage subsets with abnormal marker expression profiles specific to lymphoma types.
- Demonstration that markers beyond CD163 and CD68 (S100A9, CCR2, CD36, Slan, CD32) are crucial for characterizing lymphoma-specific TAMs.
- Close correlation found between abnormal macrophage populations and the phenotype of intra-tumor T-cell populations, including PD-1 expressing T cells.
Conclusions:
- Distinct macrophage populations exist within lymphoma tumors, differing from normal macrophages.
- Macrophage polarization is closely linked to T-cell functional states in the tumor microenvironment.
- Targeting TAMs represents a promising strategy for cancer immunotherapy in lymphoma.
Abstract:
Tumor-associated macrophage and T-cell subsets are implicated in the pathogenesis of diffuse large B-cell lymphoma, follicular lymphoma, and classical Hodgkin lymphoma. Macrophages provide essential mechanisms of tumor immune evasion through checkpoint ligand expression and secretion of suppressive cytokines. However, normal and tumor-associated macrophage phenotypes are less well characterized than those of tumor-infiltrating T-cell subsets, and it would be especially valuable to know whether the polarization state of macrophages differs across lymphoma tumor microenvironments. Here, an established mass cytometry panel designed to characterize myeloid-derived suppressor cells and known macrophage maturation and polarization states was applied to characterize B-lymphoma tumors and non-malignant human tissue. High-dimensional single-cell analyses were performed using dimensionality reduction and clustering tools. Phenotypically distinct intra-tumor macrophage subsets were identified based on abnormal marker expression profiles that were associated with lymphoma tumor types. While it had been proposed that measurement of CD163 and CD68 might be sufficient to reveal macrophage subsets in tumors, results here indicated that S100A9, CCR2, CD36, Slan, and CD32 should also be measured to effectively characterize lymphoma-specific tumor macrophages. Additionally, the presence of phenotypically distinct, abnormal macrophage populations was closely linked to the phenotype of intra-tumor T-cell populations, including PD-1 expressing T cells. These results further support the close links between macrophage polarization and T-cell functional state, as well as the rationale for targeting tumor-associated macrophages in cancer immunotherapies.

